Re-appointment of Chairman and Managing Director of the Company, Subject to the Approval of the Members at the ensuing 40th Annual General Meeting of the Company.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jenburkt Pharmaceuticals' Board approved standalone audited results for FY25 (ended March 31, 2025), with revenue from operations rising about 6.8% year-on-year to Rs. 151.69 crore and profit after tax jumping roughly 23.4% to Rs. 32.06 crore (EPS at Rs. 72.65 vs Rs. 58.86 last year). The Board has recommended a dividend of 180% on the Rs. 10 face value equity share (around Rs. 18 per share) for FY25, subject to shareholder approval. The Board also re-appointed Ashish Uttam Bhuta (DIN: 00226479) as Chairman and Managing Director for another five-year term effective April 1, 2026 to March 31, 2031, along with his remuneration for three years. The 40th AGM has been scheduled for July 18, 2025 via video conferencing, and the statutory auditor D.R. Mehta & Associates issued a clean (unmodified) opinion on the financial statements.
For shareholders, this is a positive update: strong double-digit profit growth combined with a generous 180% dividend signals healthy cash generation and rewards existing investors. The continuation of the existing promoter-CMD for another 5-year term provides leadership stability, though it still requires shareholder approval at the upcoming AGM.